Can a targeted drug combo boost tumor clearance in rare kidney tract cancer?
NCT ID NCT07741448
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial is investigating whether giving a combination of gemcitabine and trastuzumab rezetecan before surgery can improve outcomes for people with HER2-positive upper tract urothelial carcinoma, a rare cancer of the kidney's drainage system. Participants will receive four cycles of the drug combination before their planned surgery, and those without a complete response may receive two additional cycles after surgery. The main goal is to see how often the tumor completely disappears after this pre-surgical treatment, while also monitoring side effects and long-term outcomes like recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine combined with trastuzumab rezetecan
- What this could lead to
- If successful, this combination could become a new pre-surgery treatment option for HER2-positive upper tract urothelial carcinoma, potentially improving the chance of eliminating the tumor before surgery and reducing recurrence.
- What could go wrong
- This is a phase II trial with a modest number of participants, so results may not be definitive. The treatment may cause side effects, and the combination's effectiveness compared to standard care is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTUC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog
RECRUITINGWuhan, Hubei, 430030, China
-
Huanggang Central Hospital
RECRUITINGHuanggang, Hubei, 438000, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430079, China
-
Jingzhou Central Hospital
RECRUITINGJingzhou, Hubei, 434020, China
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, Hubei, 430060, China
-
Taihe Hospital
RECRUITINGShiyan, Hubei, 442000, China
-
The Central Hospital of Wuhan
RECRUITINGWuhan, Hubei, 430014, China
-
Xiangyang Central Hospital
RECRUITINGXiangyang, Hubei, 441021, China
-
Yichang Central People's Hospital
RECRUITINGYichang, Hubei, 443003, China
-
Zhongnan Hospital of Wuhan University
RECRUITINGWuhan, Hubei, 430071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.